Director/PDMR Shareholding
Source: RNS
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Director/PDMR Shareholding
Chief Financial Officer purchases 70,000 shares; Non-Executive Chairman purchases 15,435 shares
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received notification that Charles Spicer, Non-Executive Chairman of Creo, and Richard Rees, Chief Financial Officer, have purchased ordinary shares of £0.001 each in the Company ("Ordinary Shares").
Charles Spicer has purchased a total of 15,435 ordinary shares at a price of 97.18p per ordinary share. Following this transaction, Charles Spicer's total direct interest in the Company held via his Self-Invested Personal Pension ("SIPP") is now 143,411 ordinary shares, representing approximately 0.08% of the Company's issued share capital.
Richard Rees has purchased a total of 70,000 ordinary shares at a price of 96.75p per ordinary share; 21,400 of these shares are held via his SIPP. Richard Rees' total direct interest in the Company is now 73,615 ordinary shares, representing 0.04% of the Company's issued share capital.
Enquiries:
|
Creo Medical Group plc |
|
|
Richard Rees (CFO) |
+44 (0)1291 606 005 |
|
|
|
|
Cenkos Securities plc |
+44 (0)20 7397 8900 |
|
Stephen Keys / Camilla Hume (NOMAD) |
|
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
|
|
Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black / Duncan Monteith |
+44 (0)20 7260 1000 |
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
|
Paul McManus / Sam Allen / Phillip Marriage |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Charles Spicer |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Creo Medical Group plc |
|||
|
b)
|
LEI
|
213800H188ZDCWWXFA21 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
|||
|
|
|
||||
|
Identification code |
GB00BZ1BLL44 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares via SIPP |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
97.18p |
15,435 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
N/A - single transaction |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
26 May 2022 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||||
|
a)
|
Name
|
Richard Rees |
||||||
|
2
|
Reason for the notification
|
|||||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||||
|
a)
|
Name
|
Creo Medical Group plc |
||||||
|
b)
|
LEI
|
213800H188ZDCWWXFA21 |
||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
||||||
|
|
|
|||||||
|
Identification code |
GB00BZ1BLL44 |
|||||||
|
|
|
|||||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
Purchase of Ordinary Shares via SIPP
|
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
|
||||||
|
|
|
|||||||
|
- Aggregated volume |
70,000 |
|||||||
|
|
|
|||||||
|
- Price |
£67,725.00 |
|||||||
|
|
|
|||||||
|
e)
|
Date of the transaction
|
26 May 2022 |
||||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
